This is not the most recent version of the article. View current version (1 DEC 2015)

Intervention Protocol

You have free access to this content

Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy

  1. Kelvin KW Chan1,*,
  2. Anne-Marie Glenny2,
  3. Susan Furness2,
  4. Helen V Worthington2

Editorial Group: Cochrane Oral Health Group

Published Online: 28 FEB 2013

DOI: 10.1002/14651858.CD010341


How to Cite

Chan KKW, Glenny AM, Furness S, Worthington HV. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD010341. DOI: 10.1002/14651858.CD010341.

Author Information

  1. 1

    Princess Margaret Hospital, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada

  2. 2

    School of Dentistry, The University of Manchester, Cochrane Oral Health Group, Manchester, UK

*Kelvin KW Chan, Sunnybrook Odette Cancer Centre, Princess Margaret Hospital, 2075 Bayview Avenue, Toronto, Ontario, M4N3M5, Canada. kelvin.chan@sunnybrook.ca.

Publication History

  1. Publication Status: New
  2. Published Online: 28 FEB 2013

SEARCH

This is not the most recent version of the article. View current version (01 DEC 2015)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

Primary objectives

  • To determine whether molecularly targeted therapies, in addition to surgery and/or chemotherapy and/or radiotherapy for oral cavity or oropharyngeal cancers result in increased overall survival, disease free survival, progression free survival, locoregional control and reduced recurrence.

  • To determine whether immunotherapies, in addition to surgery and/or chemotherapy and/or radiotherapy for oral cavity or oropharyngeal cancers result in increased overall survival, disease free survival, progression free survival, locoregional control and reduced recurrence.

Secondary objectives

  • To determine whether molecularly targeted therapies, in addition to surgery and/or chemotherapy and/or radiotherapy for oral cavity oropharyngeal cancers are associated with increased quality of life, harm, costs and patient satisfaction.

  • To determine whether immunotherapies, in addition to surgery and/or chemotherapy and/or radiotherapy for oral cavity or oropharyngeal cancers are associated with increased quality of life, harm, costs and patient satisfaction.